IL6 and hepatocellular carcinoma: As the deletion of Akt1 and Akt2 genes in hepatocytes results in liver damage, hepatocyte death, inflammation, and the secretion of inflammatory cytokines, including IL-6, leading to STAT3 activation in surviving hepatocytes, which can potentially lead to their transformation [298], it is ill-advised to treat obese patients or those with pre-existing liver injury with pan-AKT inhibitors, as these groups of patients may be prone to developing hepatocellular carcinoma (HCC) if liver injury is sustained.